Taiwan FDA to Start Pilot Testing of eCTD Submissions
On 22nd March 2021, Taiwan FDA announced a plan on pilot testing of eCTD submission. To ensure that the …
Taiwan FDA Issues eCTD Specifications and Validation Criterion
In order to promote Taiwan’s adoption of ICH Electronic Common Technical Document (eCTD) format of , applicants will be able …
Taiwan’s Guidance on Registration of Artificial Intelligent / Machine Learning-Based Software as a Medical Device (AI/ML-Based SaMD)
The Taiwan Food and Drug Administration has released a guideline pertaining to the application of artificial intelligence related to medical …
Taiwan FDA has Amended the Regulations for Good Clinical Practice in Consideration of ICH E6(R2)
The changes are with the consideration of the ICH E6(R2), key changes are: Article 23: sponsor’s subsidies and payments provided …
Taiwan Implements GMP/GDP for API Manufacturers
Taiwan FDA has announced that API manufacturers must 1) from 27 July 2020, API manufacturers (including those only for export) …
Taiwan Publishes a Separate Standards of Review Fees for the Registration of Western Medicines
Standards or Review Fees for the Registration of Western Medicines Considering the increase in complexity and novelty of the western …
Taiwan Guideline for Basic Considerations for Real World Evidence for Drug Development
The use of Real-world Data (RWD) to produce appropriate Real-world Evidence (RWE) as a basis or supplement for drug efficacy …
Taiwan Issues Guidance on In-Vitro Companion Diagnostic Devices (CDx)
The Taiwan FDA issues on 16 July 2020 the guidance on in-vitro companion diagnostic devices (CDx), which are aimed to …
Taiwan to Conduct GCP Inspection in Compliance with New Drug Applications
Taiwan Food and Drug Administration (FDA) published a guideline on 28 May 2020 to improve the efficiency of new drug …
More News
#pharmaceuticalindustry
#regulatoryaffairs
ASEAN
Australia
Biologics/Biosimilars
Canada
China
Clinical Trials
Cosmetics
eCTD
EU
Global
Health Supplements
Herbal/Traditional Medicines
Hong Kong
India
Indonesia
Japan
Malaysia
Medical Devices
New Zealand
Pharmaceutical Drugs
Philippines
regulatory
Singapore
South Korea
Sri Lanka
Switzerland
Taiwan
Thailand
United Kingdom
United States
Vietnam